vimarsana.com

Page 27 - நிறுவனம் ஸ்டாக் விருப்பம் திட்டம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Banyan Gold Corp : Banyan Gold Announces Voting Results From Annual General and Special Meeting of Shareholders

Banyan Gold Corp.: Banyan Gold Announces Voting Results From Annual General and Special Meeting of Shareholders Banyan Gold Corp. (the Banyan ) ( TSXV:BYN) is pleased to announce the voting results of the Company s Annual General and Special Meeting of Shareholders held on January 14, 2021 (the Meeting ). Shareholders approved the business items of fixing the number of directors at four, including the election of each director nominee. Detailed voting results are as follows: Votes For 0.01% Shareholders also approved: (i) the appointment of John J. Geib, Chartered Accountant, as the Company s auditors and authorized the directors to set the auditor s remuneration; and (ii) a resolution approving the renewal of the Company s Stock Option Plan.

Core One Labs Inc : Core One Labs Completes Sale of Non-Core Assets

Core One Labs Inc.: Core One Labs Completes Sale of Non-Core Assets Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the Company or Core One ) is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,000,000 plus the assumption of approximately USD$4,000,000 in related liabilities. The completion of this sale allows the Company to focus its core business on the continued development of psychedelic alternative medicines and experiential therapies, and its CannaStrip TM delivery technology.

Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale,

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale, . Victory Square Technologies Inc.January 11, 2021 GMT Victory Square Health received Brazilian ANVISA approval for Safetest 15 Minute Covid-19 Rapid Test for distribution, sale, and usage in Brazil The Safetest 15 Minute Covid-19 Rapid Test has a 96.6% Sensitivity, and can confirm whether one is currently infected with the Covid-19 virus or whether one was infected prior and unaware of the infection On November 17th, 2020, the Company announced a strategic partnership with Molkom Pharmaceuticals to sell and distribute its Safetest Covid-19 Rapid and other Tests in Brazil and for export to Mercosur Countries

Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale, Distribution & Use of Safetest 15 Minute Covid-19 Rapid Test for Brazil

Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale, Distribution & Use of Safetest 15 Minute Covid-19 Rapid Test for Brazil Victory Square Technologies Inc. Vancouver, British Columbia, CANADA Victory Square Health received Brazilian ANVISA approval for Safetest 15 Minute Covid-19 Rapid Test for distribution, sale, and usage in Brazil The Safetest 15 Minute Covid-19 Rapid Test has a 96.6% Sensitivity, and can confirm whether one is currently infected with the Covid-19 virus or whether one was infected prior and unaware of the infection On November 17th, 2020, the Company announced a strategic partnership with Molkom Pharmaceuticals to sell and distribute its Safetest Covid-19 Rapid and other Tests in Brazil and for export to Mercosur Countries

Canntab Therapeutics Limited: Canntab Announces Closing of Convertible Debenture Private Placement

Canntab Therapeutics Limited: Canntab Announces Closing of Convertible Debenture Private Placement Canntab Therapeutics Limited. (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) ( Canntab or the Company ), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing of a non-brokered private placement (the Offering ) of secured convertible debentures of the Company ( Convertible Debentures ), pursuant to which the Company issued Convertible Debentures for gross proceeds of $1,575,000 (the Convertible Debentures ). The proceeds will be used to fund working capital for the Company, and for general corporate purposes. The Convertible Debentures are convertible into common shares of the Company (each, a

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.